Revolution Medicines, Inc. Deferred Offering Costs
Revolution Medicines, Inc. (RVMD) had Deferred Offering Costs of $600.00 thousand as of 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Balance Sheet
us-gaap:DeferredOfferingCosts · last filed 2023-02-27
- 2022-12-31: Deferred Offering Costs $600.00K.
- 2021-12-31: Deferred Offering Costs $500.00K.
- 2020-12-31: Deferred Offering Costs $0.00.
- 2019-12-31: Deferred Offering Costs $2.10M.
| Period end | Deferred Offering Costs |
|---|---|
| 2022-12-31 | $600.00K 10-K · filed 2023-02-27 |
| 2021-12-31 | $500.00K 10-K · filed 2023-02-27 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2019-12-31 | $2.10M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |